Literature DB >> 3695962

Lectin-specific targeting of lysosomal enzymes to reticuloendothelial cells.

G J Murray.   

Abstract

The principles and methods used for enzymatic modification of the carbohydrate portion of glucocerebrosidase are similar to those performed by Ashwell and Morell, Stahl, and others. It is difficult to explain the lack of uptake of native enzyme through binding of the high-mannose type glycopeptide to Man/GlcNAc receptors since approximately 20% of the total oligosaccharides on the native enzyme are high mannose type. Possibly a requirement for multiple sites of attachment to the receptor is not met by a single high-mannose type oligosaccharide per molecule. Alternatively, the presence of complex type oligosaccharides on this enzyme, demonstrated by structural studies, may mask the mannose site and thus account for the poor uptake of native enzyme. The ability to successfully deglycosylate any protein or enzyme in order to specifically target a selected cell type requires that there be (1) an available source of pure enzyme; (2) specific exoglycosidases of high specific activity available either commercially or relatively easily purified; (3) chemical or biochemical means available for the testing of the product, preferably at each step; and (4) a means of separating the glycosidases used from the desired enzyme product. The characteristic and unique accumulation of glucocerebroside only in cells of the monocyte- histiocyte series, makes Gaucher's disease an excellent prototype for the study of enzyme replacement therapy. The principles demonstrated for the enzymatic deglycosylation of glucocerebrosidase may be applied to the cell-specific delivery of other glycoproteins as well. Other lysosomal diseases in which storage occurs in multiple cell types may be ameliorated by administration of macrophage-directed enzymes if, by so doing, storage material can be digested during the normal phagocytic turnover of senescent cells. Consideration of the kinetics of degradation and the structural features affecting the stability of enzymes in vivo are prerequisites to improving the bioengineering of targeted lysosomal enzymes. Animal and culture models have been developed for the study of glucocerebrosidase delivery to specific cell types and substrate degradation. Other studies have progressed toward a definition not only of the receptors at the plasma membrane involved in the internalization of exogenous enzyme, but also of internal receptors or properties of the lysosome responsible for intracellular protein trafficking. A complete understanding of the forces acting to direct endogenous or exogenously supplied enzyme to a given subcellular organelle will require a synthesis of experimental results from all areas of glycoprotein research.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3695962     DOI: 10.1016/0076-6879(87)49041-1

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  18 in total

Review 1.  New biotechnological and nanomedicine strategies for treatment of lysosomal storage disorders.

Authors:  Silvia Muro
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2010 Mar-Apr

2.  Strategies for delivery of therapeutics into the central nervous system for treatment of lysosomal storage disorders.

Authors:  Silvia Muro
Journal:  Drug Deliv Transl Res       Date:  2012-06-01       Impact factor: 4.617

3.  Enhancement of drug delivery: enzyme-replacement therapy for murine Morquio A syndrome.

Authors:  Shunji Tomatsu; Adriana M Montaño; Vu Chi Dung; Amiko Ohashi; Hirotaka Oikawa; Toshihiro Oguma; Tadao Orii; Luis Barrera; William S Sly
Journal:  Mol Ther       Date:  2010-03-23       Impact factor: 11.454

Review 4.  Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy.

Authors:  Ricardo J Solá; Kai Griebenow
Journal:  BioDrugs       Date:  2010-02-01       Impact factor: 5.807

Review 5.  Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.

Authors:  Melani Solomon; Silvia Muro
Journal:  Adv Drug Deliv Rev       Date:  2017-05-11       Impact factor: 15.470

Review 6.  Modifying exogenous glucocerebrosidase for effective replacement therapy in Gaucher disease.

Authors:  R O Brady; G J Murray; N W Barton
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

7.  Binding, internalization, and degradation of mannose-terminated glucocerebrosidase by macrophages.

Authors:  Y Sato; E Beutler
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

8.  Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice.

Authors:  Jonathan H LeBowitz; Jeffrey H Grubb; John A Maga; Deborah H Schmiel; Carole Vogler; William S Sly
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-19       Impact factor: 11.205

Review 9.  Alglucerase. A review of its therapeutic use in Gaucher's disease.

Authors:  R Whittington; K L Goa
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

10.  Down-regulation of mannose receptors on macrophages after infection with Leishmania donovani.

Authors:  N Basu; R Sett; P K Das
Journal:  Biochem J       Date:  1991-07-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.